Xcout Intel
Prostatype Genomics competitors & alternatives
The 12 closest competitors and alternatives to Prostatype Genomics among health care companies — ranked by similarity to what Prostatype Genomics actually does, not by market-cap band.
Subscribe to see Prostatype Genomics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Prostatype Genomics
Prostatype Genomics develops, manufactures, and markets Prostatype, a prognostic genetic test for prostate cancer. The test combines gene expression data with clinical parameters to assess cancer aggressiveness and help doctors and patients determine appropriate treatment decisions.
Prostatype Genomics at a glance
Prostatype Genomics is a health care company headquartered in Sweden. Xcout tracks 6 named people at Prostatype Genomics, including Anders Liljeblad (Chariman of the Board).
Prostatype Genomics leadership
- Anders LiljebladChariman of the Board
- Anders LundbergBoard member
- Dr. Michael HäggmanBoard Member
- Håkan EnglundBoard Member
- Jörgen DahlströmBoard member
- Mattias PrageBoard Member
Top 12 Prostatype Genomics competitors
Ranked by semantic similarity — how close each company is to Prostatype Genomics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Healthcare
A3P Biomedical is a Swedish private diagnostics company that specializes in advanced prostate cancer screening. Its lead product, Stockholm3, combines protein markers, genetic markers, and clinical data using an advanced algorithm to detect aggressive prostate cancer.
Healthcare
EarlyDiagnostics, also known as EarlyDx, is a clinical-stage precision diagnostics company that develops non-invasive liquid biopsy technologies and genomics platforms for early cancer detection.
Healthcare
Cyted Health delivers a diagnostic platform that combines minimally invasive cell collection with high-resolution molecular analysis. This platform is designed to detect early biological markers.
Healthcare
Orchid Health, Inc. provides whole-genome embryo screening services for individuals and couples undergoing in vitro fertilization (IVF). The company's testing evaluates embryos for genetic predispositions to thousands of conditions, including cancers, neurodevelopmental disorders, and heart defects, to help patients mitigate hereditary health risks.
Healthcare
Innocras is a genomic analysis and cancer big data company founded in South Korea by physician-scientists from KAIST, maintaining research and corporate presence in both the United States and Korea. The company specializes in advanced cancer diagnostics and genomic technology to support precision oncology.
Healthcare
4baseCare is an Illumina-backed company headquartered in Singapore, focused on developing cutting-edge Precision Oncology Solutions using Advanced Genomics. The company also provides free NGS-biomarker testing for eligible lung cancer patients across India.
Healthcare
Celsee Diagnostics is a company operating in the rare disease diagnostics and liquid biopsy market. Based in Maryland, the company is involved in developing and assessing advanced healthcare technologies for cancer and genomic detection.
Biotechnology
EcoGenome LLC is a biotechnology company that develops diagnostic tests and kits for cancer, specifically focusing on prostate cancer. The company identifies individual tumor genetic vulnerabilities to help inform precise therapy planning and treatment choices for patients.
Biotechnology
ExosomeDx (Exosome Diagnostics) develops noninvasive liquid-biopsy diagnostics based on RNA carried in exosomes, including the ExoDx Prostate test for assessing prostate-cancer risk. Its products serve urologists, oncologists, laboratories, and patients by supporting clinical decision-making without relying solely on invasive biopsy.
Life Sciences
Pathwork Diagnostics developed molecular diagnostic tests for cancer, notably the Tissue of Origin test, which analyzes tumor gene-expression patterns to help identify the likely primary site of metastatic cancers when the origin is unknown. Its products served pathologists and oncologists managing patients with cancers of unknown primary.
Healthtech (Diagnostics)
Nanostics develops precision health technologies, specifically offering an AI-powered platform called ClarityDX. Its primary product, ClarityDX Prostate, uses clinical data and blood-based biomarkers to assess a patient's risk of aggressive prostate cancer, helping patients and healthcare providers make informed screening and testing decisions.
Biotech
MDxHealth SA is a commercial-stage precision diagnostics company specializing in urological solutions, with operations spanning the United States, the Netherlands, Belgium, Spain, Poland, Italy, the wider European Union, and various other international regions. The firm offers advanced genomic tests for prostate cancer, including SelectMDx, a non-invasive urine diagnostic, and ConfirmMDx, an epigenetic test. These innovative tools enable medical professionals to identify clinically significant prostate cancer while reducing the need for invasive procedures that carry potential complications. Incorporated in 2003, MDxHealth SA is headquartered in Herstal, Belgium, having changed its name from OncoMethylome Sciences SA in October 2010.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Prostatype Genomics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Prostatype Genomicsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →